Inventor

Changyou Zhou

Inventor

Princeton, NJ, US

Overview

2002–2020

Patent span

Human necessities

Primary field (CPC A)

Patents· 38 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

A61Pprimary

A61PSpecific therapeutic activity of chemical compounds or medicinal preparations32%

C07DHeterocyclic compounds32%

A61KPreparations for medical, dental or toiletry purposes20%

Y02ATechnologies for adaptation to climate change5%

C07CAcyclic or carbocyclic compounds4%

C07FAcyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium4%

C07BGeneral methods of organic chemistry2%

C07KPeptides1%

PatentTitleYear

10,864,203Combination of a PD-1 antagonist and a RAF inhibitor for treating cancer2020 10,647,7145 or 8-substituted imidazo[1,5-a]pyridines as indoleamine and/or tryptophane 2,3-dioxygenases2020 10,576,087Fused tricyclic compounds as Raf kinase inhibitors2020 10,562,899Fused tricyclic urea compounds as Raf kinase and/or Raf kinase dimer inhibitors2020 10,501,467Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as PARP inhibitors2019 10,457,680Process for preparing a PARP inhibitor, crystalline forms, and uses thereof2019 10,351,559Maleate salts of a B-RAF kinase inhibitor, crystalline forms, methods of preparation, and uses therefore2019 10,280,1635 or 8-substituted imidazo[1, 5-a] pyridines as indoleamine and/or tryptophane 2, 3-dioxygenases2019 10,208,038Fused tricyclic urea compounds as Raf kinase and/or Raf kinase dimer inhibitors2019 10,112,952Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as PARP inhibitors2018 9,920,055'Fused tricyclic urea compounds as raf kinase and/or raf kinase dimer inhibitors'2018 9,895,376'Fused tricyclic compounds as Raf kinase inhibitors'2018 9,827,226Substituted 5-(3,5-dimethylisoxazol-4-yl)indoline-2-ones2017 9,670,231'Fused tricyclic amide compounds as multiple kinase inhibitors'2017 9,670,203'Fused tricyclic urea compounds as Raf kinase and/or Raf kinase dimer inhibitors'2017 9,617,273'Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as PARP inhibitors'2017 9,393,232'Substituted 5-(3,5-dimethylisoxazol-4-yl)indoline-2-ones'2016 9,328,111'Substituted cycloocta[5,6]pyrido[4,3,2-de]phthalazines as PARP inhibitors'2016 9,273,046'Fused tricyclic compounds as Raf kinase inhibitors'2016 9,260,440'Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as PARP inhibitors'2016 9,079,930'Substituted pyrimidines'2015 9,034,851'Substituted pyrimidines'2015 9,006,433'Substituted pyrimidines'2015 8,039,484'Antidiabetic bicyclic compounds'2011 7,786,305'Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity'2010 7,759,493'Antidiabetic bicyclic compounds'2010 7,598,243'Heterocyclic cyclopentyl tetrahydroisoquinoline and tetrahydropyridopyridine modulators of chemokine receptor activity'2009 7,557,120'Aminocyclopentyl fused heterotricylicamide modulators of chemokine receptor activity'2009 7,514,431'Piperidinyl cyclopentyl aryl benzylamide modulators of chemokine receptor activity'2009 7,410,961'2,6-disubstituted piperiddines as modulators'2008 7,393,844'Tetrahydropyranyl cyclopentyl heterocyclic amide modulators of chemokine receptor activity'2008 7,390,803'Tetrahydropyranyl cyclopentyl benzylamide modulators of chemokine receptor activity'2008 7,361,765'Process for the preparation of CCR-2 antagonists'2008 7,247,725'Gamma-aminoamide modulators of chemokine receptor activity'2007 7,230,008'Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity'2007 7,166,614'Tetrahydropyranyl cyclopentyl tetrahydroisoquinoline modulators of chemokine receptor activity'2007 6,812,234'Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity'2004 6,387,932'Somatostatin agonists'2002

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

2002–2009Patents assigned to MERCK & CO INC (11)· patent assignee history

2002–2010Based in Plainsboro, NJ, US· patent location history

2004–2015Patents assigned to MERCK SHARP & DOHME (8)· patent assignee history

2010–2020Based in Princeton, NJ, US· patent location history

2015–2016Patents assigned to ZHOU CHANGYOU (4)· patent assignee history

2015–2017Based in Beijing, CN· patent location history

2016–2020Patents assigned to BEIGENE LTD (20)· patent assignee history

2016Patents assigned to REN BO (2)· patent assignee history

Inventor activity

Assignee and location history derived from the patent record.

Assignees

Assignee	Patents	Span
BEIGENE LTD	20	2016–2020
MERCK & CO INC	11	2002–2009
MERCK SHARP & DOHME	8	2004–2015
ZHOU CHANGYOUself	4	2015–2016
REN BO	2	2016

Locations

Location	Patents	Span
Princeton, New Jersey, US	22	2010–2020
Plainsboro, New Jersey, US	13	2002–2010
Beijing, CN	3	2015–2017